Eli Lilly (LLY) announced positive topline results from the novel TOGETHER-PsA open-label Phase 3b trial

Eli Lilly's positive results from the TOGETHER-PsA trial suggest a robust advancement in treating psoriatic arthritis, particularly for patients with obesity.

Newsquawk StaffPublished 8 Jan 2026, 19:21 UTCOn the live feed at 19:01 UTC — 3 more headlines followed before this page went public

Newsquawk headlinesUTC

19:05

CBO estimates US GDP growth to accelerate to 2.2% in 2026; unemployment to be 4.6% in 2026 and 4.4% in 2028; and the EFFR to decrease to 3.4% in 2026

19:04

Treasury Buyback (Liquidity Support): Accepts USD 2bln of 28.65bln offers, accepts 1 issue of the 35 eligible

19:01

Eli Lilly (LLY) announced positive topline results from the novel TOGETHER-PsA open-label Phase 3b trial

19:00

Colombian PPI YoY (Dec) Y/Y -2.63% vs. Exp. -1.0% (Prev. -1.45% )

19:00

Argentine Industrial Production YoY (Nov) Y/Y -8.7% vs. Exp. -1.4% (Prev. -2.9%)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free

Free. No signup, no card.

TOGETHER-PsA open-label Phase 3b trial evaluated the concomitant use of Taltz and Zepbound compared to Taltz alone in adults with active psoriatic arthritis and obesity or overweight with at least one weight-related condition
At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis activity based on ACR50 in addition to ≥10% weight reduction with concomitant Taltz and Zepbound compared to Taltz monotherapy.
Adverse events in participants treated with concomitant administration of Taltz and Zepbound were generally mild to moderate, and the types of adverse events were consistent with the known safety profile of each medicine.

Context

This could enhance the company's growth outlook and strengthen its competitive positioning in the pharmaceuticals sector as investors weigh the implications on future sales and market share across biotech competitors.

Equities · last 90 days

Recent headlines that moved markets

EQUITIES/8 Sept · 05:24 UTC

Saudi Energy Minister says a number of energy facilities and utilities were hit; are temporarily halting some operations.

Equity indices, after we published−0.3%

Modest downside seen across equity futures as energy prices tick higher.

EQUITIES/3 Sept · 04:54 UTC

North Korea stripped references to "peaceful unification" with South Korea from the charter of its ruling Workers' Party of Korea, according to Yonhap.

Equity indices, after we published−3.3%

EQUITIES/1 Sept · 16:17 UTC

Initial reports of an American attack on Iran, reports i24's Stein.

ES, after we published−0.2%

EQUITIES/26 Aug · 12:56 UTC

States and Meta (META) and agree to settle claims that platforms harmed children, according to a court filing; Meta agrees to pay a maximum of USD 16.68bln to states as part of deal

Market, after we published+2.6%

EQUITIES/10 Sept · 20:10 UTC

Oracle (ORCL) Q1 2027 (USD): Adj. EPS 1.92 (exp. 1.73), Revenue 19.3bln (exp. 19.13bln).

Market, after we published+10.1%

EQUITIES/10 Sept · 11:52 UTC

Yemeni Houthis are on the verge of complete control over the Bab al-Mandab Strait with control over the city of "Al-Mukha", IRNA reports.

Equity indices, after we published−0.4%

Newsquawk Daily

Get both market opens in your inbox.

This note and the other one — the EU open and the US open, every business day, written by the desk. No account needed.

Related headlines

The whole workspace, free to try.

© 2026 Newsquawk. All rights reserved.